Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Main Article Content

Nicole Lioufas
Alan Street
Paul Champion de Crespigny
Stephen G. Holt

Keywords

anti-retroviral, HIV, tenofovir alafenamide, tenofovir disoproxil fumarate, tubulotoxicity

Abstract

Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity.

Abstract 1209 | PDF Downloads 393 HTML Downloads 408 XML Downloads 167

References

1. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Ppveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
2. Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: A prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 2014;9(3):e92717. http://dx.doi.org/10.1371/journal.pone.0092717
3. Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, et al. A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Res Treat. 2014;10(11):35.
4. Smith ER, Cai MM, McMahon LP, Wright DA, Holt SG. The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. Nephrol Dial Transplant. 2012;27(4):1534–41. http://dx.doi.org/10.1093/ndt/gfr708
5. Samarawickrama A, Cai M, Smith E, Nambiar K, Sabin C, Fisher M, et al. Utility of uAPR measurement in HIV infection. HIV Med. 2012;13:526–32. http://dx.doi.org/10.1111/j.1468-1293.2012.01003.x
6. World Health Organisation. Progress report 2016: Prevent HIV, test all and treat all. Geneva: World Health Organisation; 2016.
7. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–71. http://dx.doi.org/10.1016/S0140-6736(14)60164-1
8. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus. NEJM. 2003;348:702–10. http://dx.doi.org/10.1056/NEJMoa022048
9. Rao TKS, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310(11):669–73. http://dx.doi.org/10.1056/NEJM198403153101101
10. Berliner A, Fine D, Lucas G, Rahman M, Racussen L, Scheel P, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28(3):478–86. http://dx.doi.org/10.1159/000112851
11. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428–34. http://dx.doi.org/10.1038/ki.2008.604
12. Zaidan M, Lescure FX, Brocherou I, Dettwiler S, Guiard-Schmid JB, Pacanowski J, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: A clinicopathological study. Clin J Am So Nephrol. 2013;8:930–8. http://dx.doi.org/10.2215/CJN.10051012
13. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96–e138. http://dx.doi.org/10.1093/cid/ciu730
14. European Association For the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85. http://dx.doi.org/10.1016/j.jhep.2012.02.010
15. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–16. http://dx.doi.org/10.1016/S0140-6736(15)60616-X
16. Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. Acquir Immune Defic Syndr. 2016;71:530–7. http://dx.doi.org/10.1097/QAI.0000000000000908
17. Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52. http://dx.doi.org/10.1016/S1473-3099(15)00348-5
18. Chan HLY, Fung S, Seto WK, Chuang W-L, Chen C-Y, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–95. http://dx.doi.org/10.1016/S2468-1253(16)30024-3
19. Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol. 2017;10(7):707–16. http://dx.doi.org/10.1080/17512433.2017.1323633
20. World Health Organization. 3: Antiretroviral agents – Therapeutic use. In: World Health Organization, editor. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Chapter 4: Clinical Guidelines Antiretroviral Therapy, 2nd ed. Geneva: World Health Organization; 2016. p. 72–190.
21. WHO. Transition to new antiretroviral drugs in HIV programmes: Clinical and programatic considerations. Geneva: WHO; 2017.
22. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119(1):1–7. http://dx.doi.org/10.1016/j.bcp.2016.04.015

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>